Thursday, January 14, 2016

StockGoodie Nasdaq IMNP - Immune Pharmaceuticals Inc.

IMNP - Immune Pharmaceuticals Inc.

Company Overview


Immune Pharmaceuticals Inc. (NASDAQ: IMNP) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.

The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma.

The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells.

The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors.

Immune is headquartered in the U.S., with its primary research and development facilities in Israel.

Immune Pharmaceuticals Inc (NASDAQ:IMNP) Receives Consensus Rating of “Strong Buy” from Brokerages
January 12th, 2016

Immune Pharmaceuticals Inc (NASDAQ:IMNP) has earned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus price objective of $6.38 for the company and are forecasting that the company will post ($0.16) EPS for the current quarter, according to Zacks. Zacks has also given Immune Pharmaceuticals an industry rank of 75 out of 265 based on the ratings given to its competitors. Read Full Article Here

Product Pipeline





Neuropathic pain describes a group of symptoms caused by damage to nerves. Central neuropathic pain may occur when nerves within the brain or spinal cord are damaged, for example spinal cord injuries, multiple sclerosis and strokes.

However, peripheral neuropathic pain is much more common and results from damage to nerves outside of the brain and spinal cord. These peripheral nerves carry sensations (feeling) to the brain and control the movement of our arms and legs. They also control the bladder and bowel.


Neuropathic pain can be very difficult to treat with only 40-60% of patients achieving partial relief.

Treatments currently used to treat neuropathic pain include local anesthetic patches (lidocaine), anti-depressant medicines (e.g., duloxetine and amitryptiline), anti-convulsants (e.g., pregabalin, gabapentin and carbamazepine) or opioids for severe, chronic pain.


AmiKet contains a combination of amitriptyline and ketamine in a topical formulation.

The combination of amitriptyline and ketamine in a cream have been shown to synergistically act to relieve neuropathic pain at the local level.

Cancer Therapeutics


CrolibulinTM is a novel small molecule vascular disrupting agent, or VDA, and apoptosis inducer for the intended treatment of patients with solid tumors. Crolibulin is being studied by the National Cancer Institute in a Phase II study for the treatment of anaplastic thyroid cancer (“ATC”). Crolibulin TM has shown promising vascular targeting activity with potent anti-tumor activity in pre-clinical in vitro and in vivo studies and in a Phase I clinical trial. To date over 100 patients have received Crolibulin TM,

The molecule has been shown to induce tumor cell apoptosis and selectively inhibit growth of proliferating cell lines, including multi-drug resistant cell lines. Murine models of human tumor xenografts demonstrated Crolibulin TM inhibits growth of established tumors of a number of different cancer types. In preclinical animal tumor models, combination therapy has demonstrated synergistic activity with cytotoxic drugs as well as anti-angiogenic drugs, such as Avastin. This may support further development of Crolibulin TM in a variety of cancers other than ATC, including but not limited to refractory ovarian cancer and neuro-endocrine tumors.

Azixa® (verobulin)

Azixa® (verobulin) is a Vascular Disruptive Agent in development for the treatment of primary brain cancers and metastatic tumors with brain involvement. Azixa® is a novel small molecule drug candidate that acts as a microtubule destabilizing agent, causing arrest of cell division and programmed cell death, or apoptosis, in cancer cells. Several currently marketed clinically effective drugs share the identical mechanism of action. Importantly, however, Azixa® has two distinguishing characteristics. In non-clinical studies, Azixa® has demonstrated the unique ability to effectively cross the blood-brain barrier and reach concentrations in the brain which are as much as 30 times that measured in the plasma. In addition, Azixa® does not appear to be subject to multiple drug resistance (MDR) mechanisms.

Two Phase 2a clinical studies demonstrated that:

Azixa®, in combination with standard chemotherapy, resulted in durable responses with no additive toxicity in patients with glioblastoma multiforme (GBM) or metastatic melanoma.

Azixa® in monotherapy resulted in durable responses in GBM patients who had failed both first and second line therapy.

Azixa® has received orphan drug status in the U.S. for the treatment of glioblastoma multiforme (GBM).

Strategic Partners

Yissum is the technology transfer company of the Hebrew University of Jerusalem (HU).The University's range of intellectual property includes inventions and know-how in many fields, including nanotechnology, medicine and pharmaceuticals, agriculture and nutrition, water and environmental technologies, computer science, homeland security, and more. Over the past 40 years, Yissum has granted more than 450 technology licenses and is responsible for commercializing an array of successful products that generate over $1 billion in worldwide sales every year. More than 60 spin-off companies, including Mobileye, Keryx, Nasvax, and Novagali have had their start at Yissum. More information is available on Yissum's website.

iCo Therapeutics Inc. trades on the TSX Venture Exchange. Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. Immune Pharmaceutical has licensed Bertilimumab (iCo-008) for systemic uses. Bertilimumab is a human monoclonal antibody targeting eotaxin-1 (eotaxin). The drug was originally developed by Cambridge Antibody Technology (now MedImmune, the biologics division of AstraZeneca) .iCo Therapautics licensed in the drug from CAT before granting Immune an option to in-license bertilimumab for non-ophthalmic indications. iCo retains the rights for the ophthalmic indications. More details can be found on their website,

IMMUNE has licensed the GS system from Lonza for the manufacturing process of Bertilimumab, planning several GMP batches including one in 2012 in anticipation of phase II clinical trials. Headquartered in Basel, Switzerland, Lonza's approach is to provide broad development and manufacturing package to their customers. Publically traded on the Zurich Stock Exchange, Lonza is one of the world leaders in contract manufacturing of monoclonal antibodies and recombinant proteins using mammalian cell culture. This program was established over 25 years ago, just one of many paths the company has followed since its founding in 1897. Please visit for more information on the company.

Financials & Filings

News Disclaimer:
Press Releases have not been investigated by StockGoodies LLC, therefore we have no idea if the content of this news is based on Fact or Fiction. Although the link for the following press release may be from a familiar and reputable news source, you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. StockGoodies LLC will not be held responsible for any news release, including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.

PR Newswire(Tue, Jan 12)
Immune Pharmaceuticals Announces 2016 Immuno-Oncology Plan

PR Newswire(Mon, Jan 4)
Immune Pharmaceuticals Announces New Data with Topical Cyclosporine Nano-Capsules in Dermatology

PR Newswire(Mon, Dec 28)
Immune Pharmaceuticals Announces Exclusive License to a Novel Bispecific Antibody Technology\

PR Newswire(Mon, Dec 14)
Immune Pharmaceuticals Announces New Data with Bi-Specific Antibody

PR Newswire(Wed, Dec 9)
Immune Pharmaceuticals CEO Updates Shareholders On Company Progress


USA Offices – 430 East 29th Street
Suite 940
New York, NY 10016
Tel: 646-440-9310 | eFax:( 1)917-398-1915

Israel Offices – 11C Galgale Haplada (1st Floor)
Herzliya-Pituach, 46722, Israel.
Tel: +972 9 886-6612 | Fax:+972 9 886-6613

Goodies Newsletter Sign Up


TEXT "Stock" to 31279

Follow Us on Twitter

Follow Us on Facebook

Follow Us on PennyStockTweets

Contact Us